再鼎医药（09688.HK）今日盘中大涨5.15%，主要受到公司发布的2025年第一季度财务业绩超出市场预期的推动。
根据公司公告，再鼎医药2025年第一季度总收入达1.06亿美元，同比增长22.19%。其中，产品收入净额为1.057亿美元，同比增长21%，按固定汇率计算增长23%。值得注意的是，公司经营亏损同比收窄20%，经调整后收窄25%，显示出公司运营效率的持续提升。
再鼎医药总裁兼首席运营官Josh Smiley表示，公司正稳步迈向2025年第四季度实现盈利的目标。展望未来，包括贝玛妥珠单抗和KarXT在内的后期管线产品，将与卫伟迦共同推动公司业绩的下一轮增长。公司重申了2025年全年收入指引为5.6亿至5.9亿美元，体现了管理层对公司发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.